

Supplemental Digital Content 4. Time course of mHLA-DR antigen expression for each patient in the (A) 480 mg nivolumab group and (B) 960 mg nivolumab group

BL, baseline; mHLA-DR, monocyte HLA-DR.
The mHLA-DR reference line is at 8000 mAb/cell.

